newsfilter
← Latest News
GlobeNewswire·

Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update

End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in Moderate PGHD Met